Fig. 6. Tumor drivers may predict the response to dapagliflozin as an adjunct to paclitaxel.

a–e Survival in EMT6, Ac711, M6, M158, and Eph 1424 tumor-bearing mice, respectively. Mice were examined daily by an investigator who was blinded as to group allocation. **P < 0.01 vs. vehicle, ++P < 0.01 vs. dapagliflozin, ##P < 0.01 vs. paclitaxel by the Mantel-Cox log-rank test, adjusted for multiple comparisons. The P values in the upper right corner of each survival curve refer to the overall curve comparison using the Mantel-Cox log-rank test. Groups of n = 5 were studied.